FLVCR2 and breast carcinoma: Others have used CCT subunits to predict disease outcomes which helped stratify breast cancer patients for treatment (70) or utilized as a liquid biopsy marker to monitor the progress of glioma patients (71), and even acted as a serum liver cancer biomarker in colorectal cancers (27).